Hi SRF Mipomersen (previously ISIS 301012) is a cholesterol-reducing drug candidate. Mipomersen completed two separate phase-3 trials with two more Phase 3 trials to be presented in mid-2010. I dont think this can be compared to ATL 1 2 or 3 because they are completely different compounds targeting completely different diseases hence comletely different mRNA structures.
Validation yes, but this completely shows its a candidate and needs validation as does the entire Antisense products.
Thats why i point out the extreme early stages particularly for ANP, and throwing magic numbers ghere and there is crazy when the company needs urgently to restructure its financial base. What that will be is anyones guess. These are my points however i see yours and thats why i was a buyer at .006 to .009. Hope that helps. Cheers Rob
ANP Price at posting:
20.0¢ Sentiment: None Disclosure: Held
